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ABSTRACT
Austin Heath Carroll: Assembly of a Protein-based Hydrogel as a Vehicle for In Situ
Drug Delivery (Under the direction of Dr. Susan Pedigo)
The goal of this work is to develop a self-assembling, protein-based gel to deliver
drugs at the site of chronic inflammation. There are two engineered protomers that
comprise the gel; calmodulin- and M13- are their critical components. Numerous
enzymes have been shown to undergo calcium-dependent regulation by calmodulin, an
intracellular protein highly resilient to its chemical environment. One of these enzymes,
myosin light chain kinase, contains a remarkable 26 residue portion known as the M13
peptide that has been demonstrated to bind to calmodulin in the presence of calcium
through hydrophobic interactions. Because the extracellular space in vivo constitutes an
environment rich in calcium, mixtures of engineered proteins with M13 (called PMSP)
and calmodulin (called CMSP) will form a network. These engineered protein mixtures
can be functionalized with drugs for delivery to the extracellular space at sites of chronic
inflammation. This two component binding system can be tuned to modify the affinity
and cooperativity with which self-assembly occurs, thus making it the perfect vehicle for
in situ drug delivery. The purpose of the work reported here is to study the M13 peptidecontaining protomer, PMSP. Since this is a novel construct, this thesis reports basic
studies of the bacterial expression, solubility, interactions with calmodulin, and evidence
that it forms a gel with CMSP. In order to obtain PMSP sufficient for hydrogel formation,
we have bacterially expressed the protein. We have found PMSP to express poorly, with

iv

yields increased upon expression from freshly transformed cells. Further, PMSP has
limited solubility in aqueous solutions, requiring the addition of Guanidine HCl or
DMSO to solubilize it. Once in solution, we found that the aqueous solubility of PMSP
increased in the presence of free calmodulin implying that PMSP bound calmodulin.
Secondly, PMSP appeared to bind to CMSP in the presence of calcium and to form a
viscous solution. We are actively working to develop spectroscopic methods to support
the apparent calmodulin-PMSP binding data. Finally, we will report our first attempts to
measure the viscosity of the PMSP and CMSP mixture.
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INTRODUCTION

Inflammation is a critical response to injury or infection that provides the body
with the ability to destroy pathogenic invaders and to repair damaged tissues 1. During
these acute periods, inflammation increases blood flow and recruits immune cells to the
point of grievance leading to pain and swelling 2. This inflammatory process is sequential
with checkpoints in place to ensure that immune cell recruitment, microbe destruction,
tissue liquefaction, and tissue repair occur in the correct order 3. When this sequential
process is disrupted, a holding pattern known as chronic inflammation occurs. While
acute inflammation promotes tissue repair, chronic inflammation in diseases such as
cancer, diabetes, cardiovascular disease, endometriosis, sciatic nerve pain and various
autoimmune disorders 4 actually further damages tissues and oxidizes DNA 3. Chronic
inflammation also causes local acidification in the tissues 5 and the release of matrix
metalloproteinases that remodel the extracellular space 6. Treatment is necessary to
circumvent and combat the destructive aspects of chronic inflammation.
The most common treatment for chronic inflammation is the use of non-steroidal
anti-inflammatory drugs (NSAIDS) like aspirin, acetaminophen, and ibuprophen 7. These
drugs must be administered orally or intravenously, however, and are systemically
distributed to all tissues. This systemic distribution leads to toxicity in the liver, kidneys,
and GI tract. Over periods of chronic use, or as a result of extreme dosage, this collateral
damage leads to organ failure 8. The purpose of our system is thus to create an injectable,
protein-based hydrogel capable of self-assembly in vivo that will bioconjugate with
NSAIDs to deliver them to the extracellular space in a controlled manner. By
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accomplishing this task, we will help circumvent the issue of NSAID toxicity and will
provide a method for controlling chronic inflammation. As this system is developed, it is
highly probable that the hydrogel will be useful in delivering other types of drugs as well.
Our protein-based hydrogel exploits the binding properties of two intracellular
proteins: calmodulin (CaM) and M13. Calmodulin is an acidic, 148 residue amino acid
protein that acts as a calcium-dependent regulator in a number of intracellular processes
(Figure 2a) 9. These processes range from signal transduction pathways involving the
calmodulin-Ca2+ kinases (CaMK I-VI), AMPA receptor recycling in neurons 10, and
smooth muscle contraction in an interaction with a specific portion of myosin light chain
kinase (MLCK) 11. This highly specific interaction of CaM with MLCK is the basis of the
interactions between the protomers in our hydrogel (Figure 1). As CaM binds M13, the
previously unstructured M13 peptide assumes a helical shape, and the CaM protein
becomes more compact 12.

Figure 1. Calmodulin – Peptide Interaction: CaM (depicted in blue) binds tightly
to a 26 amino acid portion of the enzyme myosin light chain kinase (depicted in red)
when in the presence of calcium. When this binding occurs, the peptide develops a
helical shape from a previously unstructured state while calmodulin becomes more
compact.
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MLCK is an enzyme present in smooth muscle that contains a 26 amino acid
sequence known as M13 (Figure 2b). This M13 sequence is critical for calcium
dependent muscle contraction. As calcium enters the cellular cytoplasm, it binds to CaM
(Kd = ~1 µM C-terminus, Kd = ~10 µM N-terminus), which then binds to the M13 portion
of MLCK resulting in muscle contraction 13. This binding occurs through hydrophobic
interactions with very high affinity (Kd = < 10 nM) and is the basis for the formation of
our hydrogel 14. Because calcium is present in much greater concentrations in the
extracellular space than inside the cytoplasm, our calmodulin-based component will be
saturated with calcium and capable of binding the M13 component when injected into the
extracellular space.

Figure 2a: Calmodulin’s structure, properties, and amino acid sequence
Ribbon drawing of calmodulin and AA sequence: Ribbon drawing of calmodulin with
calcium binding sites shown in yellow. Helices lead into and out of each site. The “central helix” separates
two independently folded domains. When calcium binds, hydrophobic surface area is exposed at the base of
each pair of sites.

Figure 2b: M13’s structure, properties, and amino acid sequence
Ribbon drawing of M13 and AA sequence: Ribbon drawing of M13 demonstrating the
peptide’s inherent lack of structure. As binding with calmodulin occurs through hydrophobic interactions,
however, the peptide assumes a helical structure.
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PROTEIN DESIGN

Description of Protomers
Our experimental design makes use of two protomers derived from bacterially
expressed, synthetic genes: one containing M13 and the other containing CaM. The M13based protomer (PMSP for Peptide-Modification-Sequence-Protein) is the primary focus
of this thesis and involves two repeats of M13 separated by “two cleavable modification
sequences” (Figure 3). These modification sequences are similar to collagen and are sites
for degradation by matrix metalloproteinases that are present in the extracellular space
and increasingly secreted during times of inflammation 6. PMSP also contains a 6histidine sequence for Histag purification as well as a cysteine residue on the C-terminus
that allows for the formation of a disulfide linkage to another PMSP in oxidizing
conditions. The two repeats of M13 within the protomer provide high affinity binding
sites for the calmodulin-based protomer when in the presence of calcium. The
calmodulin-based protomer (CMSP) is nearly identical to PMSP and contains two
sequences of CaM separated by two collagen-like sequences. Like the PMSP component,
it also contains a 6-histidine sequence on the N-terminus for purification and a terminal
cysteine on the C-terminus for creating a disulfide linkage with identical protomers
(Figures 3a and 3b).
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Figure 3a: CMSP and PMSP Constructs
Depictions of CMSP and PMSP: Each protomer contains a Histag sequence depicted in green and
black, two repeats of CaM or M13, two repeats of a collagen—like sequence (CLS), and a terminal
cysteine.
Figure 3b: Formation of Protomer Dimers
Depiction of Dimer Formation
Under oxidizing conditions, the C-terminus cysteine residues allow the protomers to form disulfide
linkages. This allows for the formation of four binding sites on each of the constructs.

Hydrogel Design
Our design makes use of the inherent properties of a hydrogel, which is a 3D
network of crosslinked polymers that retain high amounts of water and demonstrate
elasticity and strength similar to bodily tissues 15. Through the use of biomaterials
capable of binding in response to extracellular calcium, our hydrogel will self-assemble
and respond to inflammation. Through a collaborative project with the Watkins lab, we
will bioconjugate NSAIDs to the calmodulin protomer through ester linkages, and the gel
will respond to the increased acidity in the extracellular space during times of
inflammation. As the pH decreases, the ester linkages will be hydrolyzed and the drug
will be increasingly delivered. Degradation of the gel by proteases and consequent drug
release will also be further accelerated by the increased release of matrix
metalloproteinases during times of inflammation. As needed, the composition, size, and
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drug dosage of the hydrogel can be modified, making it the perfect vehicle for in situ
drug delivery.

Structure of the Thesis
Since PMSP is a completely novel protein, there is no precedence for its
properties. As we worked with this engineered protein, we encountered a number of
unexpected results that then drove the next steps. We present this “odyssey” as it
unfolded, and while the story is still developing, this thesis documents the path so far.

SCOPE OF WORK

To obtain PMSP, we transformed BL21DE3 Rosetta cells with a pET30 plasmid
containing our gene that confers kanamycin resistance (Figure 4a). By growing our cells
on agar plates spiked with kanamycin, we were able to successfully confirm that
transformation occurred. IPTG, a molecular mimic of allolactose, a lactose metabolite
that triggers transcription of the lac operon, was then used to induce bacterial expression
of our protein. After expression, the cells were centrifuged, sonicated and centrifuged
once more (Figure 4b). An acrylamide gel was then used to demonstrate that PMSP was
present in the post-induction pellet and in the sonicated whole cell but not in the postinduction supernatant (Figure 5a). This important piece of data revealed that PMSP is
not soluble in aqueous solutions. This forced us to recover it from the pellet. Thus, the
pellet was treated with Triton-X, a non-ionic surfactant capable of permeabilizing cell
membranes. Three washes were carried out with an initial wash using 10% Triton-X and
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two subsequent washes using 1% Triton-X. Each wash was followed by centrifugation.
Samples were taken before and after each wash, and after centrifugation for an SDSacrylamide gel (Figure 5b), which demonstrated that the protein remained in the pellet
after the 10 % TX and 1% TX washes.
In order to solubilize the pellet, we tried several strategies. First, in previous work
from our lab, Christopher Fox showed that the PMSP was not adequately solubilized in
concentrated urea. Thus, 6 M Guanidine HCl/20 mM Tris/ 140 mM NaCl/pH 7.4 was
added to the pellet. After significant vortexing, the pellet was dislodged and mixed with
the aqueous solvent. At this point, a large gelatinous material descended to the bottom of
the conical (Figure 6b), and we speculated that it could be DNA based on its appearance.
This gel was mechanically removed, washed with distilled water three times, and was
then sonicated for 30 seconds and centrifuged for 30 minutes at 3000 rpm. An SDSacrylamide gel was run to evaluate the protein in the supernatant and gel portions of the
gelatinous material (Figure 5c). A subsequent UV spectrum was also taken of the
supernatant but due to scattering of light by insoluble material, no clear signal could be
obtained.
The Triton-X, Guanidine-treated supernatant was then taken into 1 mL aliquots,
centrifuged for 8 minutes and placed on a Histag column equilibrated with Binding
Buffer + 6 M Guanidine. Wash buffers and elution buffers also containing 6 M
Guanidine were used to maintain protein solubility through the entire separation.
Subsequently, an acrylamide gel and UV-Vis spectrum revealed that PCLP had been
successfully purified for the first time (Figure 5d and Figure 6a), but that it had low
solubility in aqueous buffers. There were two elution fractions with PMSP with
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concentrations of ~ 40 µM and 100 µM. Studies described in this thesis were conducted
with the 40 µM fraction.

Figure 4a: Transformation and Induction of BL21D3
Rosetta Cells
Depiction of PMSP designed plasmid followed by
transformation and induction: The PMSP gene
contains a sequence for kanamycin resistance and a
lac operon site for the induction of expression using
IPTG
Figure 4b: Flow Chart of Transformation,
Expression, and Recovery
Establishing a cell stock, expressing PMSP, and
Purification: The protocol for PMSP purification
requires transformation of BL21D3 cells, cell
reproduction in liquid cultures, and purification using
Triton X and Guanidine.
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Figure 5a: Acrylamide gel demonstrating initial expression and sonification of PMSP
Post induction sample and sonicated whole cell: After induction with IPTG, the gel revealed that PMSP was
present at 18 kD in both the post induction sample and the sonicated whole cell sample. This indicates that PMSP
is not soluble in aqueous solution
Figure 5b: Gel demonstrating 10% and 1% triton-X washes to PMSP pellet
Triton-X Wash samples: After each subsequent round of washing with Triton-X, the gel revealed that PMSP
remained confined to the pellet further indicating insolubility
Figure 5c: Gel demonstrating TX and Guanidine treatment to PMSP Pellet and analysis of gelatinous component
Guanidine Treatment and gelatinous material analysis: Treatment with guanidine allowed the PMSP to move
into solution as shown in the gel. The gelatinous material was also demonstrated to contain PMSP.
Figure 5d: Gel demonstrating final purification of PMSP through Histag chromatography
Histag Chromatography Purification: Histag purification using binding, wash, and elution buffers containing 6
M Guanidine led to the purification of PMSP. Material visualized below 18 kD shows truncated products.

Figure 6a: UV-Vis Spectrum Demonstrating the Purification of PMSP
Figure 6b: Gelatinous material that was Mechanically Removed from PMSP after the addition of 6 M
Guanidine
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Solubility Tests
Through the expression and purification of PMSP, we have determined it is
largely insoluble in aqueous solution. It was thus necessary to carry out several solubility
tests to determine feasible solvents for mixtures with CMSP. The first test included
dialyzing a portion of PMSP stock out of aqueous guanidine and into pure DMSO.
Through this transition, the PMSP remained fully soluble, and it was determined that
DMSO was a feasible solvent for working with our protein.
The second test consisted of dialyzing a portion of PMSP into 100 mL solutions
of aqueous SEC buffer consisting of HEPES and NaCl with gradually decreasing
amounts of guanidine. The solutions ranged from 6 M, 4.5 M, 3 M, 1.5 M, and 0.5 M
guanidine. Each solution was dialyzed for approximately an hour. The PMSP remained
fully soluble until the transition from 2 M to 0.5 M guanidine. At this point, the protein
formed a heavy, white precipitate. Interestingly, no gelatinous material reformed.
Next, we hypothesized that the addition of hydrophilic CaM would increase the
aqueous solubility of PMSP. To this end, 3 mg of dry CaM and concentrated aqueous
calcium to a concentration of 1 mM were added to the precipitated solution. These two
additions did not bring the precipitated PMSP back into solution. This mixture was
dialyzed into 200 mL of 2 M guanidine/20 mM HEPES/ 140 mM NaCl/pH 7.4 (SEC
buffer) for one hour and the protein returned into solution. After this, the solution was
dialyzed into 200 mL of pure SEC buffer for 2 hours. This time, the protein remained
fully soluble in the aqueous SEC solution (Figure 7). This indicates that 1) PMSP binds
to CaM in the presence of calcium, and that 2) the binding of CaM to PMSP increases the
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solubility of PMSP.

Figure 7: Solubility Schematic of PMSP in SEC Buffer with varying Concentrations of Guanidine
Decreasing Guanidine Decreases Solubility but adding CaM and Ca2+ Increases Solubility:
As the concentration of guanidine is decreased, solubility decreases. At 0.5 M guanidine, PMSP
precipitates out of solution. As demonstrated, when CaM and Ca2+ are added, PMSP remains
fully soluble in aqueous SEC buffer. This indicates that PMSP is binding CaM.

After testing PMSP alone and in the presence of CaM, we tested the solubility of
PMSP in the presence of the CMSP protomer. This was accomplished by adding 5 mg of
dry CMSP to 1.5 mL of 40 µM PMSP in 6 M guanidine and dialyzing it against aqueous
SEC buffer. After an hour, an extremely white, heavy precipitate formed and the solution
was dialyzed into a 2 M guanidine solution. This allowed the protein to return to solution.
Finally, the solution was dialyzed against pure DMSO, and the CMSP/PMSP mixture
remained soluble.
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Formation of a Hydrogel
In order to form our first hydrogel, we concentrated the CMSP/PMSP mixture in
DMSO to 113 µM PMSP and 225 µM CMSP and added calcium to a final concentration
of approximately 50 mM. Within five minutes, the solution became turbid and took upon
the appearance of a viscous gel (Figure 8c).

50 mM Ca2+

Figure 8a: Decreasing Guanidine Concentrations Reduces PMSP Solubility
Dialysis Experiment Reducing Guanidine Concentration: Dialysis bags, shown between green
clamps, demonstrate decreased solubility as guanidine is removed. Left, PMSP is soluble in 6 M
guanidine but forms a cloudy precipitate in 0.5 M guanidine.
Figure 8b: Adding CaM and Ca2+ solubilizes PMSP in SEC Buffer
Dialysis Experiment with the Addition of CaM and Ca2+: After the addition of CaM and Ca2+,
PMSP becomes fully soluble in aqueous solution. Left, a cloudy precipitate is present in SEC buffer.
Right, PMSP is solubilized in SEC after the addition of CaM and Ca2+.
Figure 8c: Formation of our First Hydrogel
Combining PMSP and CMSP Protomers in the presence of Ca2+: Upon mixing both protomers
in high concentration in DMSO and adding calcium, a viscous and gel-like material formed.
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Synthetic Peptide Alternative
As a possible alternative for circumventing the solubility issue of the PMSP
protomer, we also designed a short 48 amino acid peptide with the following sequence:
CGGSSKRRWKKNFIAVSAANRFKKISSSGALGSREGPQGIWGQERSGC (The 26
residue M13 sequence is in bold and the collagenase cleavage sequence is underlined.
Cysteines are at the termini). To synthesize the peptide, we used a CEM peptide
synthesizer in the lab of Dr. Saumen Chakraborty with the help of Dr. Chakraborty and
Suchitra Mitra. This peptide contains the full M13 sequence and only a single collagenlike modification sequence to increase solubility. Cysteines are present at each end to
allow linkages of the peptide segments into protomers with a diversity of lengths and
geometries. Just after synthesis, the peptide was cleaved from the bead, and a MALDITOF mass was obtained of the peptide product. The mass spectrum demonstrated an
envelope of products ranging from a mass of 4.8 kD to 5.7 kD (Figure 9a), a range that
spans the expected molecular weight (5.1 kD). We are not clear as to what the envelope
of products indicates, although we have speculated that truncated products and impurities
are present in the sample. Upon analysis with an acrylamide gel using samples with BME
reducing loading buffer in DMSO and SEC solutions and a sample with non-reducing
loading buffer in SEC solution, bands were visualized at approximately 10 kD (Figure
9b). This size is the expected weight of peptide dimers, although it is unclear why
polymerization occurred regardless of whether or not reducing agent was present in the
loading buffer, and that polymerization would make only dimers. Through the use of an
Innovagen peptide properties calculator (https://pepcalc.com/ ), it was revealed that the
peptide contains a significant number of basic residues that could be preventing it from
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properly migrating in the electrophoretic field of an acrylamide gel and could thus
explain why all three bands from Figure 9b were visualized at 10 kD. As for solubility,
the peptide was found to be fairly soluble in aqueous solutions. This gives it potential for
use in the drug delivery system, and further work is necessary to functionalize the peptide
and determine how it reacts in the presence of CMSP and calcium.

Figure 9a: MALDI-TOF of Synthetic Peptide
Envelope of Products Revealed by MALDI Analysis: The crude sample from the peptide sample
revealed an envelope of products ranging from 4.8 kD to 5.7 kD. The expected weight of the
peptide was within the envelope at 5.1 kD.
Figure 9b: Acrylamide Gel of Synthetic Peptide
Acrylamide Gel with Reducing and Non-Reducing Loading Buffer: Samples in DMSO and
SEC solutions with BME reducing load were visualized as bands at 10 kD. A sample in SEC
solution with a non-reducing load was also visualized at 10 kD.
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DISCUSSION AND CONCLUSION

The experiments described above indicate that our engineered PMSP construct
has low aqueous solubility, an attribute that introduces a challenge that subverts its role
as one of two components in an aqueous hydrogel. Below we speculate on a number of
aspects of the experiments reported above and of the structure and function of PMSP in
an attempt to better understand the challenges that this protein has presented. A better
understanding of these challenges will help us to best determine the conditions for its use
in our nascent biomaterial and will allow us to design a second generation PMSP
protomer.

Bacterial Expression of PMSP
There are distinct advantages to using a bacterial expression system for making
our PMSP protomer. These expression systems are inexpensive, produce large quantities,
and provide an inexpensive method for re-engineering the gene to improve the properties
of the protomer. Our current system has several properties that we do not entirely
understand. First, in our lab, we typically store transformed expression cells as glycerol
stocks at -80 °C. The CMSP expression cells are stored in this way, yet we have found
that expression of PMSP is very poor in subsequent attempts after the first expression.
We have successfully produced PMSP from the transformed cell stocks, but in low
abundance. We have also tried an alternative cell line, and found the same phenomenon:
after storage for one to two weeks, expression levels have dropped. Thus, to obtain
decent yield upon expression, we must use freshly transformed cells. Interestingly, this is
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not required of the CMSP expression cells even though the CMSP gene is identical to the
PMSP gene except for the peptide/CaM components. There is no secondary structure
formation that we expect in the mRNA. As of yet, we don’t have an explanation for this
complication in the expression of PMSP.

PMSP’s Insolubility
From previous experience using a 100 µM M13 stock in our lab, we have
demonstrated that the M13 peptide is quite soluble in aqueous solutions. The PMSP
protomer was thus designed with the belief that it would be fully soluble. Personal
communication with Dr. Madeline Shea (University of Iowa, Department of
Biochemistry) informed us to expect that M13 would interact with negatively charged
phospholipids in the cell membrane during bacterial expression due to the fact that it
contains a significant number of positively-charged, basic residues. For this reason, we
expected that PMSP would be in the pellet fraction after sonication. We reasoned,
however, that treatment with Triton-X would dissolve and remove the cell membrane
lipid component, and increase the solubility of PMSP. As discussed above, PMSP
remained insoluble after the Triton-X washes.
Because PMSP remained in the pellet after the washes, we have been forced to
investigate other potential issues that could be causing the lack of solubility. One
promising possibility remains the number of collagen-like modification sequences within
each PMSP molecule. First, the collagen-like sequences contain hydrophobic amino
acids, no charged amino acids (GPQGIWGQ), and only two H-bond donor/acceptors.
From this inherent hydrophobicity, it is likely that the collagen-like sequences are playing
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a role in PMSP’s insolubility in aqueous solutions. The fact that the synthetic peptide
with only a single collagen-like sequence demonstrated an increased solubility over
PMSP supports this conclusion. This argument also raises the question of why the CMSP
protomer is so soluble. One explanation is that the large hydrophilic CaM components are
far larger than the collagen-like sequences and provide increased solubility. The
importance of CaM in increasing the solubility of the CMSP protomer is further
supported by the fact the PMSP protomer is only soluble in aqueous solution when in the
presence of added CaM, as discussed above.
Second, it is possible that the collagen-like sequences within multiple PMSP
protomers are aggregating with one another to form the triple helix structure that
composes collagen polymers. A brief review of the literature suggests it takes a minimum
of 36 amino acids of collagen repeats (twelve repeats of the 3- amino acid collagen
sequence) for the formation of collagen triple helixes 16. Because our material only
contains 8 amino acids in each collagen-like segment, we speculate that formation of a
full collagen triple helix is not occurring.

The Role of DMSO
In order to work with PMSP, we needed a solvent that would solubilize our
protomer. It was also important to find a solvent for biomaterial formation that is
compatible with medical applications and that would be safe when administered within
the body. We thus chose DMSO, although we are working to increase the aqueous
solubility of the peptide construct in hopes that we will be able to work in aqueous
solutions in the future.
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DMSO is an amphipathic molecule with both a highly polar sulfonyl bond, and
two non-polar methyl groups 17. It has a half-life of 16 hours within humans and can be
administered in a number of different ways for medical applications 18. The most
common routes of administration include topical administration to assist in drug delivery
and via intravesical instillation in women with interstitial cystitis 19. It is important to
note that DMSO is capable of increasing the flexibility of the phospholipid bilayer in cell
membranes and increasing the number of water pores in the membrane 20. This property
makes it particularly useful as a vehicle for drug delivery as it easily penetrates skin and
other bodily barriers. Fortunately, this membrane penetration does not cause irreversible
damage, and DMSO has been shown to have low toxicity in humans 17. This, in concert
with the fact that DMSO itself has been directly administered as a medication, makes it
an applicable solvent for our drug delivery system.
To ensure that DMSO would not prohibitively disrupt PMSP and CMSP binding,
we conducted a brief literature review on the effect that DMSO has on general protein
structure. The literature suggests that DMSO increasingly disrupts protein secondary
structure as DMSO concentration increases. This occurs primarily through the disruption
of protein hydrogen bonding networks 21. In pure DMSO, it was found that a majority of
proteins are almost completely unfolded and tend to form aggregates. Our data with
CMSP and PMSP forming a turbid material in DMSO suggests that the two protomers
are still cable of binding when in the presence of extraordinarily high concentrations of
calcium. We speculate that the high levels of calcium drive the maintenance of secondary
structure within the highly resilient CMSP and allow it to bind PMSP, which is already
unstructured. It will be necessary to conduct further binding studies between CaM and
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M13 and between PMSP and CMSP in DMSO to determine the optimum conditions for
binding. In theory, these speculations should be testable, but since DMSO has a large
absorbance in the region of the spectrum in which secondary structures absorb light, we
cannot use instrumentation routinely available to us. We are actively working on using
fluorescence to monitor the environment of the tryptophan residues as a function of CaM
binding and solvent composition.

Implications and Direction for Future Research
At this time, the CMSP component is fully functional and behaves as expected
(soluble and demonstrates calcium-dependent M13 binding). It will thus be important to
continue to study PMSP in DMSO, work to increase its aqueous solubility, and to
characterize the formation of gels. One promising alternative remains to design a gene
that contains only a single collagen-like modification sequence to increase the
hydrophilic/hydrophobic ratio of the protein. In addition, it will be important to further
investigate the gelatinous material that was removed in Figure 6b and to confirm the
increase in viscosity observed in Figure 8c through the use of rheometry. Furthermore, it
will be necessary to assess the susceptibility of the components to degradation by
proteases that will be present in the extracellular matrix. In conclusion, both protomers
have shown promise as a means to create a novel in-situ delivery system.
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APPENDIX

Appendix 1: Full Amino Acid Sequence of PMSP Protomer: This schematic
provides the full AA sequence for our protomer. The 6 histidine histag sequence is
underlined. In bold, the 28 AA sequence for the M13 peptide. The collagen-like
modification sequences are shown in boxes. Finally, the terminal cysteine is shown
in red.

22

